| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: NRPH |
| Security Type |
Common Stock |
| Lead Underwriter |
WR Hambrecht & Co LLC |
| Days In Registration |
91 |
| Date Filed |
6-May-2004 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2008) |
| Industry |
Manufacturing |
| Business Description |
Manufacture safer and improved versions of widely prescribed drugs in large and growing markets through proprietary Carrierwave technology, to develop novel pharmaceuticals to address the significant drawbacks and adverse side effects of currently marketed drugs, such as Vyvanse, formerly NRP104, which is a prodrug of amphetamine, NRP290, a prodrug of hydrocodone and NRP369, an opioid widely used to treat acute pain |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
17.76M |
| Contact |
- |
| Number of Employees |
- |
|
| Original Filing Information |
| US |
| Shares Filed |
4.2M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
4.2M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
630.0K |
| File Amount |
$50.4M |
| File Price Range |
$14.00 - $10.00 |
| File Mid Price |
$12.00 |
Current Filing Information
(Amended 5-Aug-2004) |
|
US |
|
Shares Filed |
4.2M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
4.2M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$33.6M |
| · % Change from Original |
-33.33 |
| File Price Range |
$8.00 - $8.00 |
| File Mid Price |
$8.00 |
|
